Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Geode Capital Management LLC increased its holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL) by 41.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 226,083 shares of the company’s stock after acquiring an additional 66,712 shares during the period. Geode Capital Management LLC owned about 0.55% of Vigil Neuroscience worth $769,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of VIGL. Acadian Asset Management LLC purchased a new stake in shares of Vigil Neuroscience during the 2nd quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vigil Neuroscience during the second quarter valued at about $87,000. Renaissance Technologies LLC increased its holdings in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the last quarter. Walleye Capital LLC raised its position in Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. Finally, Verition Fund Management LLC purchased a new position in Vigil Neuroscience in the third quarter valued at about $442,000. 83.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

VIGL has been the subject of several research analyst reports. JMP Securities restated a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush raised their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Friday, November 8th. Finally, William Blair started coverage on Vigil Neuroscience in a report on Wednesday, December 4th. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $19.75.

Vigil Neuroscience Price Performance

NASDAQ:VIGL opened at $1.79 on Friday. Vigil Neuroscience, Inc. has a 1 year low of $1.49 and a 1 year high of $6.06. The stock’s fifty day moving average price is $2.40 and its two-hundred day moving average price is $3.25. The company has a market cap of $73.17 million, a P/E ratio of -0.87 and a beta of 1.76.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.